Share Published on Oct 16, 2012 Health & Medicine 0 Comments Statistics Notes Be the first to like this Views Actions 0 Embeds 0 1.National Listof Essential Medicines of India 2011 Page 1 of 127 2.Page 2 of 127 3.TABLE OF CONTENTSPREAMBLE ...................................................................................................................................... 5EXECUTIVE SUMMARY .................................................................... Error!Salient features of NLEM 2011: .......................................................... Error!Bookmark not defined.The meetings/deliberations of core committee/ National consultation meetings held forpreparing the National List of Essential Medicines 2011 ............................................................. 13PROCESS ADOPTED FOR REVISION OF NLEM .............................................................................. 14POTENTIAL USES OF NLEM ........................................................................................................... 16EXPERTS WHO PARTICIPATED IN PREPARING NLEM- 2011.......................................................... 17MEDICINES ADDED IN THE NLEM 2011 ........................................... Error!

Bookmark not defined.MEDICINES DELETED FROM NLEM 2003 ...................................................................................... 30NATIONAL LIST OF ESSENTIAL MEDICINES 2011 .......................................................................... 33Section: 1 – Anesthesia ................................................................................................................. 33Section: 2 - Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicinesused to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders ................... 35Section: 3 – Antiallergics and Medicines used in Anaphylaxis ..................................................... 37Section: 4 - Antidotes and Other Substances used in Poisonings ................................................ 37Section: 5 – Anticonvulsants/ Antiepileptics ................................................................................ 39Section: 6 – Anti-infective Medicines ........................................................................................... 40Section: 7 –Antimigraine medicines ............................................................................................. 48Section: 8 –Antineoplastic, immunosuppressives and medicines used in palliative care ........... 49Section: 9 –Antiparkinsonism medicines ...................................................................................... 52Section: 10 –Medicines affecting the blood ................................................................................. 53Section: 11 –Blood products and Plasma substitutes................................................................... 54Section: 12 –Cardiovascular medicines ........................................................................................ 55Section: 13 –Dermatological medicines (Topical)......................................................................... 59Section: 14 –Diagnostic agents ..................................................................................................... 61Section: 15 –Disinfectants and antiseptics ................................................................................... 62Section: 16 –Diuretics ................................................................................................................... 63 Page 3 of 127 4.

Section: 17 – Gastrointestinal medicines ..................................................................................... 64Section: 18 –Hormones, other endocrine medicines and contraceptives ................................... 67Section: 19 Immunologicals .......................................................................................................... 69Section: 20 – Muscle Relaxants (Peripherally acting) and Cholinesterase Inhibitors .................. 72Section: 21 – Ophthalmological Preparations .............................................................................. 73Section: 22 – Oxytocics and Antioxytocics .................................................................................... 74Section: 23 – Peritoneal Dialysis Solution ..................................................................................... 76Section: 24 – Psychotherapeutic Medicines ................................................................................. 76Section: 25 – Medicines acting on the respiratory tract .............................................................. 78Section: 26 – Solutions correcting water, electrolyte and acid-base disturbances ..................... 79Section: 27 – Vitamins and Minerals ............................................................................................ 80Alphabetical List of Medicines – Therapeutic area wise .............................................................. 81Alphabetical List of Medicines in NLEM 2011............................................................................... 98List of Medicines in NLEM 2011 – Category Wise ...................................................................... 112 Page 4 of 127 5.g19 vaporizer

PREAMBLEEssential medicines are those that satisfy the priority healthcare needs ofmajority of the population.vaporizer azureusThe essential medicines list needs to be countryspecific addressing the disease burden of the nation and the commonly usedmedicines at primary, secondary and tertiary healthcare levels.siroco vaporizerThe medicinesin National List of Essential Medicines (NLEM) should be available at affordablecosts and with assured quality.best vape juice combosThe medicines used in the various nationalhealth programmes, emerging and reemerging infections should be addressedin the list.allersearch hippo deluxe steam vaporiser reviews

The Government of India, Ministry of Health & Family Welfare(MOHFW) is mandated to ensure the quality healthcare system by assuringavailability of safe and efficacious medicines for its population.The primary purpose of NLEM is to promote rational use of medicinesconsidering the three important aspects i.e.vapor shop nashua nhcost, safety and efficacy.Furthermore it promotes prescription by generic names.vaporizer vrvHealthcare deliveryinstitutions, health insurance bodies, standards setting institutions formedicines, medicine price control bodies, health economists and otherhealthcare stakeholders will be immensely benefitted in framing their policies.vaporizer vrvPage 5 of 127 6.vicks vaporizer v4500 instructions

The NLEM 2011 has been prepared after several rounds of wide consultationswith experts of different disciplines from different parts of the country andfrom various organizations.The NLEM is a dynamic document and feedback from all stakeholders iswelcome which will help in its revision at regular basis.The core committee of NLEM 2011 would like to place on record itsappreciation for the subject experts who made a significant contribution inrevision and updating the list of essential medicines of India.Page 6 of 127 7.EXECUTIVE SUMMARYThe National list of essential medicines is one of the key instruments inbalanced healthcare delivery system of a country which inter alia includesaccessible, affordable quality medicine at all the primary, secondary, tertiarylevels of healthcare.Realizing this GOI, MOHFW decided to have its ownessential medicines list.The first National List of Essential Medicines of Indiawas prepared and released in 1996.This list was subsequently revised in 2003.To address the issues of changing disease prevalence, treatment modalities,introduction of newer medicines and identification of unacceptable risk-benefit profile as well as therapeutic profile of some medicines, the GOI,MOHFW considered the need for updating the NLEM.Revision of NLEM was also based on the two important national referencedocuments i.e., Indian Pharmacopeia 2010 and National Formulary of India,4th Edition, 2010.

While the former deals with the standards of identity, purityand strength of medicines the later provides the information on rational use ofmedicines particularly for healthcare professionals.Page 7 of 127 8.In order to revise the NLEM 2003, a core committee was constituted vide orderno: 12-01/ Essential Medicines/ 08-DC dated 6th July 2010 GOI, MOHFW withfollowing members. Prof. Y. K. Gupta, Head, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi  Prof. S.K.Sharma, Head, Department of Medicine, All India Institute of Medical Sciences, New Delhi  Dr. T.S.Sidhu, Medical Superintendent, Dr. Ram Manohar Lohia Hospital, New Delhi  Dr. A. K. Harit (Chief Medical Officer) representing DDG (M), Dte.GHS, Ministry of Health & Family Welfare, New Delhi  Dr. D. Kanungo, Addl.GHS, Ministry of Health & Family Welfare, New Delhi  Dr. Chander Shekhar, Scientist F, Indian Council of Medical Research, New Delhi  Dr. Sukarma S. Tanwar, National AIDS Control Organization, New Delhi  Mr.

V. K. Tyagi, Deputy Industrial Advisor, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, New Delhi Page 8 of 127 9.N. Singh, Secretary-cum-Scientific Director, Indian Pharmacopoeia Commission, Ghaziabad  Dr. Surinder Singh, Drugs Controller General (India), Dte.GHS, Ministry of Health & Family Welfare, New DelhiThe first meeting of the core committee of NLEM was held at CDSCO on July22, 2010.The meeting was initiated by DCGI, Dr. Surinder Singh, Dr. Y. K.Gupta, Professor & Head, Department of Pharmacology, AIIMS, New Delhi wasunanimously nominated as chairman of the Committee.During this meeting the core committee was informed that the CDSCO hadalready taken an initiative in this direction and organized a workshop entitled“Expert Group Meeting on Revision and Updating of the National List ofEssential Medicines” on September 16, 2009 in collaboration with Departmentof Pharmacology, AIIMS and WHO India Office.The workshop was attended byrepresentatives from the following: CDSCO, Ministry of Health; WHO; All IndiaInstitute of Medical Sciences, New Delhi; Indian Pharmacopoeia Commission;Indian Council of Medical Research and experts of different disciplines fromleading medical and pharmacy institutions of the country.The issue of updating NLEM was also deliberated in a dedicated session duringthe Annual Conference of Indian Pharmacological Society, December 2009 at Page 9 of 127 10.

Kolkata and the session was chaired by Prof. Y K Gupta, AIIMS and Dr. KWeerasuriya, WHO-SEARO.The core committee took note of the proceedingsof these two meetings while revising the NLEM.In this core committee meeting it was deliberated that although WHO hasprepared an updated list of “Essential Medicines”, it cannot be adopted assuch.The NLEM of India should be country specific considering the diseaseprevalence, cost effectiveness of Medicines etc in the country.In the meeting the criteria for inclusion/ deletion of medicines were developedand a road map for the revision and updating of NLEM, 2003 was drawn.Sh.V. K. Tyagi from Department of Pharmaceuticals (DoP), Ministry ofChemicals & Fertilizers emphasized the importance of NLEM in view of thedirections of the Hon’ble Supreme Court of India.He also mentioned that DoPmay rely on the NLEM prepared by MOH &FW for price fixation.During the meeting it was felt that opinion/views may be taken from acrossthe country by organizing brainstorming regional workshops.

However,considering the logistics and time constraints it was decided that a Nationalconsultation meet should be organized in Delhi inviting experts from variousspecialties and from different parts of the country.Page 10 of 127 11.Accordingly “National Consultation Meet for Revision of National List ofEssential Medicines” was organized by Department of Pharmacology, AIIMS &Central Drugs Standard Control Organization (CDSCO), Ministry of Health andFamily Welfare on December 3-4, 2010.The meet was supported by WHOIndia office.Experts from different disciplines from medical andpharmaceutical institutes, hospitals from across the country and concernedgovernment agencies participated.After initial briefing, four groups wereformed according to therapeutic areas.The groups were asked to specificallygive the reasons/evidence which guided their decision regardingaddition/deletion/alteration.Subsequently the recommendations of theindividual groups were discussed in the open house.Thereafter the draftrecommendations of the Workshop were prepared with general consensus.The recommendations of the Workshop were further deliberated upon by theExpert Core Committee on 4th Jan 2011 and 31st Jan 2011 at CDSCO.

Therevised NLEM 2011 has thus been prepared.The Expert Core Committee recommended that all the medicines which arebeing provided under various National Health Programmes are considered asessential medicines.Page 11 of 127 12.Salient features of NLEM 2011:The medicines have been categorized according to therapeutic area.Thereforeit is possible that a medicine with more than one indication appears in morethan one category.The issue of mentioning the strength of the medicine dose was deliberated.The committee took the considered view that the strength should bementioned in the NLEM.For essentiality of requirement the medicines have been categorized asfollows: - P, S and T denote essentiality at Primary, Secondary and Tertiary levels respectively while P, S, T (U in NLEM 2003) indicates essentiality at all the levels.A total of 348 medicines (excluding repetitions) are present in NLEM 2011.Inthe NLEM 2011, 181 medicines fall under the category of P, S and T, 106medicines fall under the category of S, T while 61 medicines are categorized asT only.

In comparison to NLEM 2003, number of medicines deleted is 47 and 43medicines have been added.Page 12 of 127 13.The meetings/deliberations of core committee/ National consultation meetings held for preparing the National List of Essential Medicines 2011Core Committee Meetings 1.The first meeting was held at CDSCO, FDA Bhawan on July 22, 2010 2.The second meeting was held at CDSCO, FDA Bhawan on January 4, 2011 3.The third meeting was held at CDSCO , FDA Bhawan on 31st Jan,2011National Consultation Meetings 1.The first consultation meet was held on September 16, 2009 at Department of Pharmacology, AIIMS, New Delhi 2.The second National consultation meet was held on December 3-4, 2010 at Department of Pharmacology, AIIMS, New DelhiOther Deliberations: 1.A dedicated session on National Essential Medicine List was organized during 42nd Annual conference of Indian Pharmacological Society, on 11th December, 2009 at Swabhumi, Kolkata Page 13 of 127 14.PROCESS ADOPTED FOR REVISION OF NLEM National List of Essential Medicines 2003 (Base document) Consultation meetings with ExpertsDeliberation on Evidence based criteria for addition and deletion of medicines from the NLEM Therapeutic area wise group discussion (Group composition: Clinicians, Pharmacologists, Pharmacists, Scientists and Regulators) REVISION PROCESS contd… Page 14 of 127 15.

Presentation by groups in open house discussion Resource Materials:Resource Support:  WHO Model List of EssentialScientists, Senior Residents, Medicines 2010,  WHO model formulary,Junior Residents and PhD  National Formulary of IndiaScholar of Dept of 2010 (Pre print Version),Pharmacology, AIIMS, New  Textbooks of Pharmacology,Delhi Internal Medicine,  Drug compendia,  Indian Pharmacopoeia,  Internet facility Deliberations/ discussion and reasoning for additions/ deletions/modifications Draft recommendations for NLEM Consideration and adoption of NLEM by the Core Committee Page 15 of 127 16.POTENTIAL USES OF NLEMThe concept of essential medicines, first introduced by WHO in 1977, has now been adoptedby many countries, non-governmental organizations and international non-profit supplyagencies.The list is considered to include the most cost-effective medicines for a particularindication.It is developed in concordance with the standard treatment guidelines keeping inmind the healthcare needs of the majority of the population.

Careful selection of a limitedrange of essential medicines results in a higher quality of care, better management ofmedicines and more cost-effective use of health resources.The list of essential medicines guides the hospital drug policies, procurement and supply ofmedicines in public sector, medicine cost reimbursement and medicine donations.It helpsin monitoring the pricing of medicines.The list serves as a reference document for correctdosage form and strength for prescribing.Preference is given to single drug formulations asopposed to fixed dose combinations where appropriate.Hence use of NLEM is expected toimprove prescribing practices as well as the health outcomes.The appropriate use ofmedicines selected in the NLEM promotes rational use of medicines.Such rational use ofmedicines, especially antimicrobial drugs, reduces development of drug resistance.The listalso serves as a reference for assessing the healthcare access of the populace.Lastly, NEMLserves as a tool for public education and training of healthcare providers.

Page 16 of 127 17.EXPERTS WHO PARTICIPATED IN PREPARING NLEM- 2011 Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Joint Drug Controller (India),1.A B RAMTEKE CDSCO, FDA Bhawan, Regulatory   Body Kotla Road, New Delhi Assistant Drug Controller,2.A K PRADHAN CDSCO, FDA Bhawan, Regulatory   Body Kotla Road, New Delhi Associate Professor,3.of Medicine, Medicine   AIIMS, New Delhi Professor,4.ARTI KAPIL Dept of Microbiology, Microbiology   AIIMS, New Delhi Dean and Director Professor ARUN K Department of ENT5.AGARWAL Maulana Azad Medical College ENT --  New Delhi Technical Officer,6.ASEEM SAHU CDSCO, FDA Bhawan, Regulatory   Body Kotla Road, New Delhi Professor,7.of Cardiology, Cardiology  --- BHARGAVA AIIMS, New Delhi Page 17 of 127 18.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Associate Professor,8.

BIKASH MEDHI Department of Pharmacology, Pharmacology   PGIMER, Chandigarh Asst.PADHY Department of Pharmacology Pharmacology √  HIMSR, Jamia Hamdard Professor and Head,10.C D TRIPATHI Dept.of Pharmacology, Pharmacology  -- Vardhman Medical College and Hospital, New Delhi Medical Superintendent,11.D K SHARMA AIIMS, Medicine   New Delhi Addl.DG (Stores), DGHS, MOHFW, Nirman12.D. KANUNGO Bhawan, MOHFW --  New Delhi Professor,13.of Obstetrics & Gynaecology  -- Gynaecology, AIIMS, New Delhi.Prof & Head G Dept.PARTHASARATHI JSS College of Pharmacy and Pharmacy ---  JSS Medical College Mysore Technical Officer,15.GAURAV KUMAR CDSCO, FDA Bhawan, Regulatory   Body Kotla Road, New Delhi Page 18 of 127 19.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Secretary-cum-Scientific Director,16.GN SINGH Indian Pharmacopeia Pharmacy , --  Commission, Govt of India , Ghaziabad Assistant Professor,17.

of Pharmacology, Pharmacology  √ AIIMS, New Delhi Principal Scientist,18.JAI PRAKASH Indian Pharmacopoea Pharmacy   Commission , Govt of India Ghaziabad Jt.Advisor JANARDAN Department of AYUSH,19.PANDEY MOHFW ---  Ministry of health and Family Welfare ,Govt of India Associate Professor,20.of Pharmacology, Pharmacology   AIIMS, New Delhi Department of Hospital Hospital21.JITENDRA Administration, Administratio --  AIIMS, New Delhi n Asstt.Professor Department of Dermatology & K D BARMAN Dermatology22.STD, and STD --  Maulana Azad Medical College New Delhi Assistant Professor,23.K H REETA Dept.of Pharmacology, Pharmacology   AIIMS, New Delhi Page 19 of 127 20.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Professor and Head,24.K K PANT Dept.of Pharmacology, Pharmacology   CSM Medical College and Hospital, Lucknow Professor and Head,25.K K SHARMA Dept.of Pharmacology, Pharmacology  --- UCMS, New Delhi Regional Adviser Essential Drugs and Medicines26.

K WEERASURIYA Policy Clinical  -- Pharmacology World Health Organization – SEARO Professor,27.of Pharmacology, Pharmacology  -- AIIMS, New Delhi Professor and Head,28.M C GUPTA Dept.of Pharmacology, Pharmacology  -- PGIMS, Rohtak, Haryana NPO Essential Drugs and Medicines Clinical29.MADHUR GUPTA WHO country office for India Pharmacology --  Professor and Head,30.of Neurology, Neurology   AIIMS, New Delhi Associate Professor,31.of Neurology, Neurology  -- TRIPATHI AIIMS, New Delhi Page 20 of 127 21.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Director Professor MK DAGA Department of Medicine32.Maulana Azad Medical College Medicine ---  New Delhi Department of Medicine33.MPS CHAWLA RML Hospital, New Delhi Medicine ---  Associate Professor34.of Pharmacology Pharmacology ---  SMS Medical college, Jaipur Professor,35.N R BISWAS Dept.of Pharmacology, Clinical  -- Pharmacology AIIMS, New Delhi Professor,36.

of Pharmacology, Pharmacology   UCMS, New Delhi NASEEM SHAH Chief, Professor and Head37.Centre for Dental Education Dental  --- and Research Medicine AIIMS, New Delhi Associate Professor,38.AJOY Centre for Dental Education Dental --  ROYCHAUDHURY and Research Medicine AIIMS, New Delhi Associate Professor Obstetrics NEENA39.MALHOTRA Department of Obstretics and and ---  Gynaecology, AIIMS, New Delhi gynecology Dy.NEENA VALECHA National Institute of Malaria and Malaria  -√-- Research, experti Dwarka, New Delhi Page 21 of 127 22.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Emeritus Scientist,41.O P AGARWAL Indian Council of Medical Pharmacology  --- Research, New Delhi Professor,42.P K MEDIRATTA Dept.of Pharmacology, Pharmacology   UCMS, New Delhi Department of Pharmacology Nizams Institute of Medical Clinical43.P USHA RANI Sciences, Pharmacology ---  Hyderabad Professor & Head,44.

of Pharmacy Practice, Pharmacy  --- NIPER, SAS Nagar, Mohali, Punjab Associate Professor Department of Gastroentrolo45.PRAMOD GARG Gastroenterology and Human gyysician ---  Nutrition, AIIMS, New Delhi Professor and Head,46.of Emergency Medicine, Medicine   AGGARWAL AIIMS, New Delhi Director, Health47.R C DEKA AIIMS, New Delhi.Administrator  √--- and ENT Professor ,48.R K BATRA Dept.of Anaesthesia and Anaesthesia   Intensive Care, AIIMS, New Delhi Page 22 of 127 23.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Prof & Head RAJENDRA Dept of Pulmonary Medicine Pulmonary49.PRASAD medicine ---  CSM Medical College and Hospital, Lucknow Scientist E,50.RAJNI KAUL Indian Council of Medical Basic Scientist  --- Research, New Delhi Professor RAKESH51.CHADDHA Department of Psychiatry Psychiatry ---  AIIMS Associate Professor,52.RAKESH YADAV Dept of Cardiology, Cardiology   AIIMS, New Delhi Programme Officer (CST),53.

RESHU AGARWAL NACO, New Delhi Medicine ---  Associtate Professor Dr. R P Centre for Opthalmic Sciences Ophthalmolo54.ROHIT SAXENA AIIMS gy ---  Professor and Head,55.S K TRIPATHI Dept.of Clinical Pharmacology, Clinical   Pharmacology School of Tropical Medicine, Kolkata, WB Associate Professor,56.SAMEER BAKSHI Medical Oncology, IRCH, Medical   Oncology AIIMS, New Delhi Page 23 of 127 24.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Professor & Head,57.SANDEEP Department of Pharmacology, Pharmacology  --- KAUSHAL Dayanand Medical College, Ludhiana Professor & Head,58.SANGEETA Dept of Neuropsycho Clinical   SHARMA Pharmacology, Pharmacology IHBAS, Delhi Associate Professor, Centre for Community Community59.RAI Medicine Medicine ---  AIIMS, New Delhi.Chief Pharmacist Institute of Liver and Biliary60.SEEMA DUBEY Sciences Pharmacy ---  New Delhi Medical Superintendent, R.P.Centre for Ophthalmic Sciences & Hospital61.

SHAKTI GUPTA Head, Dept.Administratio   n Administration, AIIMS, New Delhi Scientist, National Poision Information Centre ,62.SHARDA PESHIN Toxicology   Dept.of Pharmacology, AIIMS, New Delhi SHRIDHAR Professor and Head,63.DWIVEDI Department of Medicine Medicine ---  UCMS, New Delhi Page 24 of 127 25.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Associate Professor SHYAM SUNDER64.SHARMA Department of Pharmacology, Pharmacology ---  NIPER, Mohali Professor65.SK MAULIK Department of Pharmacology Pharmacology ---  AIIMS, New Delhi DDGM Community66.SK PRADHAN DGHS, MOHFW Medicine ---  New Delhi Technical Officer, Pharmacy67.SUNIL CDSCO, FDA Bhawan, Regulatory   KULSHESTRA Kotla Road, New Delhi Body National Professional Officer68.SUNIL NANDRAJ (Health Systems Development), WHO  --- World Health Organization, New Delhi Assistant Professor,69.of Pharmacology, Pharmacy and   Pharmacology AIIMS, New Delhi Medical Superintendent, ENT surgeon T.S.

RML Hospital, Administratio ---  New Delhi n TUSHAR Assistant Professor Ophthalmolo71.AGGARWAL Department of Ophthalmology gy ---  AIIMS, New Delhi Department of Hospital Administration, Hospital72.U S GARG AIIMS, New Delhi Administratio ---  n Page 25 of 127 26.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Director Professor & Head, UMA TEKUR Department of Pharmacology73.Maulana Azad Medical College, Pharmacology ---  New Delhi Professor & Head74.V K PAUL Department of Pediatrics Pediatrics  --- AIIMS, New Delhi Deputy Industrial Advisor, Dept.of Pharmaceuticals, Ministry of75.V. K. TYAGI Ministry of Chemical & Chemicals & ---  Fertilisers, Fertilizers New Delhi Assistant Professor,76.of Pediatrics, Pediatrics  --- AIIMS, New Delhi Scientist F,77.VIJAY KUMAR Indian Council of Medical Health  --- administrator Research, New Delhi Assistant Professor,78.VINAY GULATI Department of Medicine, Medicine  --- AIIMS, New Delhi Professor and Head,79.

VINOD RAINA Medical Oncology, Institute Medical  --- Cancer Rotary Hospital (IRCH), Oncology AIIMS, New Delhi VISHAL KUMAR Medical Officer80.MALHOTRA Chacha Nehru Bal Chikitsalaya Pediatrics ---  New Delhi Page 26 of 127 27.Meeting Meeting Specialization held on held onS.No NAME AFFILIATION / Department September December 16, 2009 3-4, 2010 Associate Professor Department of Medicine81.VIVEK ARYA Medicine ---  PGIMER, Dr. RML Hospital, New Delhi Professor and Head,82.Y K GUPTA Dept of Pharmacology, Pharmacology   AIIMS, New Delhi Additional Professor YASHPAL Department of Cardiology,83.SHARMA PGIMER, Chandigarh Cardiology ---  Senior Resident, Clinical84.Pooja Gupta Department of Pharmacology, Pharmacology   AIIMS, New Delhi Senior Resident, Ashish Kumar Clinical85.Kakkar Department of Pharmacology, Pharmacology --  AIIMS, New Delhi Senior Resident, Sudhir Chandra Clinical86.Sarangi Department of Pharmacology, Pharmacology   AIIMS, New Delhi Technical Associate (PvPI) Saravana Perumal87.

S Department of Pharmacology, Pharmacy   AIIMS, New Delhi Page 27 of 127 28.MEDICINES ADDED IN THE NLEM - 2011S.No.Name of the medicine 1.5-Amino salicylic Acid (5-ASA) 3.Imatinib Page 28 of 127 29.Premix Insulin 30:70 injection 37.Page 29 of 127 30.MEDICINES DELETED FROM NLEM - 2003S.No.Benzoic Acid + Salicylic Acid 4.Gamma Benzene Hexachloride 18.Mebendazole Page 30 of 127 31.Name of the medicine 23.Menadione Sodium Sulphite 24.Thiacetazone + Isoniazid 44.Trifluoperazine Page 31 of 127 32.Name of the medicine 46.Xylometazoline Page 32 of 127 33.NATIONAL LIST OF ESSENTIAL MEDICINES 2011 Section: 1 – Anesthesia 1.1 General Anesthetics and Oxygen Medicines Category Route of Administration Strengths Ether S, T Inhalation --Halothane with vaporizer S, T Inhalation Isoflurane S, T Inhalation 10 mg / ml, Ketamine Hydrochloride P, S, T Injection 50 mg / ml Nitrous Oxide P, S, T Inhalation Oxygen P, S, T Inhalation 0.5 g, 1 g Thiopentone Sodium S, T Injection powder Added Medicines Sevoflurane T Inhalation 1% oil Propofol P,S,T Injection suspension 1.2 Local Anesthetics Medicines Category Route of Administration Strengths 0.25%, 0.5%, 0.5%Bupivacaine Hydrochloride S, T Injection to be mixed with 7.5% glucose Page 33 of 127 34. solution 2-5%, Topical Forms, 1-2%,Lignocaine Hydrochloride P, S, T Injection, 5% +7.5% Spinal GlucoseLignocaine Hydrochloride 1%, 2% + + Adrenaline P, S, T Injection Adrenaline 1:200,000 Added Medicines EMLA cream T Cream 1.3 Preoperative Medication and Sedation for Short Term Procedures Medicines Category Route of Administration Strengths Atropine Sulphate P, S, T Injection 0.6 mg / ml P,S,T Tablets 5 mg Diazepam Injection, 5 mg / ml Syrup, 2mg/5ml S, T Suppository 5 mg 1 mg / ml Midazolam P, S, T Injection 5 mg / ml Morphine Sulphate S, T Injection 10 mg / ml Promethazine P, S, T Syrup 5 mg / 5 ml Page 34 of 127 35.

Section: 2 - Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders 2.1: Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti- inflammatory Medicines Route ofMedicines Category Strengths Administration Acetyl P, S, T Tablets 325, 350 mgSalicylic Acid T Tablets 50 mg Diclofenac T T Injection 25 mg / ml Tablets 200 mg, 400 mg Ibuprofen P, S, T 100mg/5ml Syrup P, S, T Injection 150 mg / ml P, S, T Syrup 125 mg / 5ml P, S, T Tablets 500 mgParacetamol Suppository P, S, T 80 mg, 170 mg Is this commonly used ??/ 2.2 Opioid AnalgesicsMedicines Category Route of Strengths Page 35 of 127 36.Administration Morphine Injection 10 mg / ml Sulphate S, T Tablets 10 mg Added medicines Tramadol Injection 50 mg/ml S,T Cap 50 mg,100 mg Fentanyl S,T Injection 50ug/ml 2ml ampoule 2.3 Medicines used to treat Gout Allopurinol S, T Tablets 100 mg Colchicin S, T Tablets 0.5 mg 2.4 Disease modifying agents used in Rheumatoid disorders Azathioprine S, T Tablets 50 mgMethotrexate S,T Tablets 5, 7.5, 10mgSulfasalazine S, T Tablets 500 mg Added medicinesHydroxychloro quine S,T Tablets 200 mg phosphateLeflunomide S,T Tablets 10,20 mg tab Page 36 of 127 37.

Section: 3 – Antiallergics and Medicines used in Anaphylaxis Medicines Category Route of Administration Strengths Adrenaline P, S, T Injection 1 mg / ml BitartrateChlorpheniramine P, S, T Tablets 4 mg Maleate Dexchlorphenira P, S, T Syrup 0.5 mg / 5 ml mine Maleate Dexamethasone P, S, T Tablets 0.5 mg Injection 4 mg / ml Hydrocortisone P, S, T Injection 100 mgSodium Succinate Pheniramine P, S, T Injection 22.75 mg / ml Maleate Prednisolone P, S, T Tablets 5 mg, 10 mg, 20 mg Promethazine P, S, T Tablets 10 mg, 25 mg Syrup 5 mg / 5 ml Added Medicines Cetrizine P,S,T Tablets 10mg Syrup 5 mg/ml NLEM 2011 Section: 4 - Antidotes and Other Substances used in Poisonings 4.1: Nonspecific Medicines Category Route of Administration Strengths Activated P,S,T Oral Charcoal 4.2: Specific Medicines Category Route of Administration Strengths Atropine P,S,T Injection 1 mg/ml Sulphate Page 37 of 127 38.Specific P,S,T Injection Polyvalent Solution/ antisnake Lyophilyzed Polyvalent Serum venomCalcium P,S,T Injection 100mg/mlgluconate Desferrioxami S, T Injection 500mg ne mesylate Methylthioni S, T Injection 10 mg / ml nium chloride (Methylene blue) Penicillamine S, T Tablets or Capsules 250 mg Dimercaprol S, T Injection in oil 50 mg / ml Flumazenil T Injection 0.1 mg / ml Sodium S, T Injection 30 mg / ml Nitrite Sodium S, T Injection 250 mg/ ml Thiosulphate Naloxone P,S,T Injection 0.4mg/ml Pralidoxime P,S,T Injection 25 mg/ml Chloride(2- PAM) Added medicines: N- P,S,T Injection 200 mg/ml(5 ml)acetylcysteine Page 38 of 127 39.

Section: 5 – Anticonvulsants/ Antiepileptics Medicines Category Route of Administration StrengthsCarbamazepine P, S, T Tablets 100mg Syrup 200mg 100 mg/5ml Diazepam P,S,T Injection 5 mg / ml Magnesium S,T Injection 500 mg /ml sulphate Phenobarbito P,S,T Tablets 30 mg,60 mg ne ST Injection 200 mg/ml P,S,T Syrup 20 mg/5ml Phenytoin P,S,T Capsules or Tablets 50 mg, Sodium Syrup 100mg Injection 25mg/ml 50 mg/ml Sodium P,S,T Tablets 200 mg, Valproate Syrup 500mg 200 mg/5ml T Injection 100 mg/ml Added Medicines Lorazepam T Injection 2mg/ml Page 39 of 127 40.Section: 6 – Anti-infective Medicines 6.1 Anthelminthics 6.1.1 Intestinal Anthelminthics Medicines Category Route of Administration Strengths Albendazole P,S,T Tablets 400 mg Suspension 200 mg/ 5 ml Added Medicines Piperazine P,S,T Tablets 4.5 gm Solution 750mg/5ml 6.1.2 Antifilarials Medicines Category Route of Administration StrengthsDiethylcarbamazine citrate P,S,T Tablets 50 mg 6.1.3 Antischistosomals and Antitrematode Medicines Route of Medicines Category Strengths Administration Praziquantel S, T Tablets 600 mg 6.2 Antibacterials 6.2.1 Beta lactam medicines Route of Medicines Category Strengths Administration Powder for suspension 125 mg / 5 ml Amoxicillin S,T Capsules 250 mg 500 mg Capsules 250 mg, 500 mg Ampicillin P,S,T Powder for suspension 125 mg / 5 ml Injection 500 mg Page 40 of 127 41.

P,S,T Injection BenzathineBenzylpenicillin 6 lacs, 12 lacs, units Cefotaxime S, T Injection 125 mg, 250 mg 500 mg Ceftazidime S, T Injection 250mg, 1g Ceftriaxone S, T Injection 250 mg, 1 g Cephalexin P,S,T Syrup 125 mg / 5 ml Capsules 250 mg, 500 mg Cloxacillin P,S,T Capsules 250 mg, 500 mg Injection 250 mg Liquid 125mg/ 5 ml Added MedicinesAmoxicillin+Clav T Tablets 625 mg ulinic acid Powder for suspension 228.5mg/5ml Injection 600mg, 1.2gm Cefixime T Tablet 100, 200mg 6.2.2 Other antibacterials Route of Medicines Category Strengths Administration Amikacin S, T Injection 250 mg / 2 ml Tablets 100, 250,500mg Azithromycin S,T Suspension 100mg/5ml Injection 500mg Ciprofloxacin P,S,T Injection 200 mg /100 ml Hydrochloride Tablets 250 mg, 500 mg Co- Tablets Trimoxazole P,S,T 80 + 400 mg(Trimethoprim Suspension 160+800 mg + 40 + 200 mg / 5 mlSulphamethoxa Page 41 of 127 42. zole) Doxycycline P,S,T Tablets 100 mg Erythromycin Syrup 125 mg / 5 ml Estolate P,S,T Tablets 250 mg, 500 mg 10 mg / ml, 40 mg / Gentamicin P,S,T Injection mlMetronidazole P,S,T Tablet 200mg,400mg Injection 500mg/100ml Syrup 100mg/5mlNitrofurantoin P,S,T Tablets 100 mgSulphadiazine S, T Tablets 500 mg VancomycinHydrochloride T Injection 500 mg, 1 g 6.2.3 Antileprosy medicines Route of Medicines Category Strengths Administration Clofazimine P,S, T Capsules 50 mg, 100 mg Dapsone P,S, T Tablets 50 mg, 100mg Rifampicin P,S, T Capsules or Tablets 150 mg, 300 mg 6.2.4 Antituberculosis medicines Route of Medicines Category Strengths Administration Ethambutol P,S,T Tablets 200 mg, 400 mg, 600 mg, 800 mg 50 mg, 100 mg, 300 Tablets mg Isoniazid P,S,T Syrup 100 mg/5ml Tablets 100 mg, 200 mg Ofloxacin S, T Syrup 50 mg / 5 ml Page 42 of 127 43.

500 mg, 750 mg,Pyrazinamide P,S,T Tablets 1000 mg, 1500 mg 50 mg, 150 mg, 300 Capsules/Tablets mg,450 mg Rifampicin P,S,T Syrup 100 mg / 5 mlStreptomycin Sulphate P,S,T Injection 0.75 g, 1 g 6.3 Antifungal medicines Route of Medicines Category Strengths AdministrationAmphotericin B S, T Injection 50 mg Pessaries 100 mg, 200 mg, Clotrimazole P,S,T Gel 2% 50 mg, 100 mg, 150 Fluconazole mg, S, T Capsules or Tablets 200 mg Griseofulvin P,S,T Capsules or Tablets 125 mg, 250 mg Tablets 500,000 IU Nystatin P,S,T Pessaries 100,000 IU 6.4 Antiviral medicines 6.4.1 Antiherpes medicines Route of Medicines Category Strengths Administration 200 mg, 400 mg Tablets 250 mg, 500 mg Acyclovir S, T Injection 400 mg / 5 ml Suspension 6.4.2 Antiretroviral medicines 6.4.2.1 Nucleoside reverse transcriptase inhibitors Page 43 of 127 44.Route of Medicines Category Strengths Administration Didanosine S, T Tablets 250 mg, 400 mg Lamivudine S, T Tablets 150 mgLamivudine +Nevirapine + 150 mg + 200 mg+ Stavudine S, T Tablets 30 mgLamivudine + Zidovudine S, T Tablets 150 mg + 300 mg 15 mg, 30 mg, 40 Stavudine S, T Capsules mg Zidovudine S, T Tablets 100 mg, 300 mg ADDED MEDICINES Stavudine+ S,T Tablets 30mg+ 150mg LamivudineZidovudine+ S,T Tablets 300mg+Lamivudine+ 150mg+ Nevirapine 200mg 6.4.2.2 Non-nucleoside reverse transcriptase inhibitors Route of Medicines Category Strengths Administration 200 mg, Efavirenz S, T Capsules 600 mg Capsules 200 mg Nevirapine S, T Suspension 50 mg / 5 ml 6.4.2.3 Protease inhibitors Route of Medicines Category Strengths Administration Indinavir S, T Capsules 200 mg, 400 mg Page 44 of 127 45.

Nelfinavir S, T Capsules 250 mg Capsules Ritonavir S, T Syrup 100 mg400 mg / 5 ml Saquinavir S, T Capsules 200 mg 6.5 Antiprotozoal Medicines 6.5.1 Antiamoebic and Antigiardiasis medicines Route of Medicines Category Strengths Administration Diloxanide Furoate P,S,T Tablets 500 mg Tablets 200 mg, 400 mgMetronidazole P,S,T Injection 500 mg /100 ml 6.5.2 Antileishmaniasis medicines Route of Medicines Category Strengths AdministrationAmphotericin B S, T Injection 50 mg Pentamidine Isothionate S, T Injection 200 mg SodiumStibogluconate S, T Injection 100 mg / ml 6.5.3 Antimalarial Medicines 6.5.3.1 For curative treatment Route of Medicines Category Strengths AdministrationArtesunate (Tobe used only in combination with P,S,T Tablets 50 mg Sulfadoxine + Page 45 of 127 46.Pyrimethamine ) Tablets Injection 150 mg base Syrup 40 mg / ml Chloroquine phosphate P,S,T 50 mg / 5 ml Primaquine P,S,T Tablets 2.5 mg, 7.5 mgPyrimethamine P,S,T Tablets 25 mg P,S,T Tablets 300 mg Quinine sulphate ST Injection 300 mg / ml Sulfadoxine +Pyrimethamine P,S,T Tablets 500 mg + 25 mg Medicines added Clindamycin S,T Tablet 150, 300mg 6.5.3.2 For prophylaxis Route of Medicines Category Strengths Administration Medicines added Mefloquine S,T Tablet 250 mg base 6.5.4 Antipneumocystosis and Antitoxoplasmosis medicines Route of Medicines Category Strengths Administration Co- Trimoxazole Tablets(Trimethoprim P,S,T 80 + 400 mg + Suspension 160+800 mgSulphamethoxa zole) 40 + 200 mg / 5 ml Page 46 of 127 47.

Pentamidine Isothionate S, T Injection 200 mg Page 47 of 127 48.NLEM 2011 Section: 7 –Antimigraine medicines 7.1: For treatment of acute attack Route of Medicines Category Strengths AdministrationAcetyl Salicylic Acid P,S,T Tablets 300 - 350 mgDihydroergotamine S, T Tablets 1 mg Paracetamol P,S,T Tablets 500 mg 7.2: For Prophylaxis Route of Medicines Category Strengths Administration Propranolol P,S,T Tablets 10 mg, 40 mg hydrochloride Page 48 of 127 49.Section: 8 –Antineoplastic, immunosuppressives and medicines used in palliative care 8.1: Immunosuppressive medicines Route of Medicines Category Strengths Administration Azathioprine T Tablets 50 mg 10 mg, 25 mg, Cyclosporine T Capsules 50 mg, 100 mg Concentrate for 100 mg/ml Injection 8.2: Cytotoxic medicines Route of Medicines Category Strengths Administration Actinomycin D T Injection 0.5 mg Alpha Interferon T Injection 3 million IU Bleomycin T Injection 15 mg Busulphan T Tablets 2 mg 10 mg / vial Cisplatin T Injection 50 mg / vial Tablets 50 mg, 200 mgCyclophosphamide T Injection 500 mg 100 mg/vial Cytosine T Injection 500 mg/vial arabinoside 1000 mg/vial Danazol T Capsules 50 mg, 100 mg Doxorubicin T Injection 10 mg Etoposide T Capsules 100 mg Page 49 of 127 50.

Injection 100 mg/ 5 ml vial Flutamide T Tablet 250 mg 5-Fluorouracil T Injection 250 mg / 5 ml Folinic Acid T Injection 3 mg / ml Gemcitabine 200 mg T Injection hydrochloride 1 gmL- Asparaginase T Injection 5000 KU.Melphalan T Tablet 2 mg, 5 mg Tablet 50 mgMercaptopurine T Injection 100 mg / ml Tablet 2.5 mg Methotrexate T Injection 50 mg / ml Mitomycin-C T Injection 10 mg Paclitaxel T Injection 30 mg / 5 ml Procarbazine T Capsules 50 mg Vinblastine T Injection 10 mg sulphate Vincristine T Injection 1 mg / ml Added medicinesCarboplatin T Injection 150 mg, 450 mg vialDacarbazine T Injection 500 mgDaunorubicin T Injection 20 mg vial Ifosfamide T Injection 1 gm/2ml vial Mesna T Injection 200 mg Oxaliplatin T Injection 50 mg vial Imatinib T Tablets 100 mg, 400 mg Page 50 of 127 51.Chlorambucil T Tablets 2 mg 8.3: Hormones and antihormones Route of Medicines Category Strengths Administration Tablets 5 mg 20 mg,Prednisolone S, T Injection 25 mg (as sodium phosphate or succinate) Raloxifene T Tablets 60 mg Tamoxifen T Tablets 10 mg, 20 mg Citrate 8.4: Medicines used in palliative care Route of Medicines Category Strengths Administration Morphine T Tablets 10 mg Sulphate Tablets 4 mg, 8 mgOndansetron S, T Injection 2 mg/ml Syrup 2 mg/5 ml Added Medicines Filgrastim T Injection 1 ml vial Allopurinol T Tablets 100 mg Page 51 of 127 52.

Section: 9 –Antiparkinsonism medicines Route of Medicines Category Strengths AdministrationBromocriptine S, T Tablets 1.25 mg, 2.5 mg Mesylate Levodopa+ P,S,T Tablets 100 mg+10 mg Carbidopa 250 mg+25 mg 100 mg+25 mgTrihexyphenidyl P,S,T Tablets 2 mg Hydrochloride Page 52 of 127 53.Section: 10 –Medicines affecting the blood 10.1: Antianaemia medicines Route of Medicines Category Strengths AdministrationCyanocobalamin P, S,T Injection 1 mg/ml Ferrous P,S,T Tablets Tablets equivalent to 60 Sulphate/ mg elemental iron Fumrate Oral solution 25mg elemental iron (as sulphate)/ml Folic Acid P,S,T Tablets 1 mg , 5mg Iron Dextran S, T Injection 50 mg iron/ml Pyridoxine P,S,T Tablets 10 mg 10.2: Medicines affecting coagulation Route of Medicines Category Strengths Administration 1000 IU/mlHeparin Sodium S, T Injection 5000 IU/ ml Protamine S, T Injection 10 mg/ml SulphatePhytomenadione P, S, T Injection 10 mg/mlWarfarin sodium S, T Tablets 5 mg Added Medicines Enoxaparin T Injection 40mg, 60mg Page 53 of 127 54.

Section: 11 –Blood products and Plasma substitutes 11.1: Plasma Substitutes Route of Medicines Category Strengths Administration Dextran-40 P,S,T Injection 10% Dextran-70 P,S,T Injection 6% Fresh frozen T Injection plasma Hydroxyethyl Starch S, T Injection 6% (Hetastarch) Polygeline S, T Injection 3.5% 11.2: Plasma fractions for specific use Route of Medicines Category Strengths Administration Albumin S, T Injection 5%, 20 % Cryoprecipitate S, T Injection Factor VIII S, T Injection Dried Concentrate Factor IX Complex (Coagulation S, T Injection DriedFactors II,VII, IX, X) Platelet Rich S, T Injection Plasma Page 54 of 127 55.Section: 12 –Cardiovascular medicines 12.1: Antianginal medicines Route of Medicines Category Strengths Administration 75mg,Acetyl salicylic 100mg, P,S,T Tablets acid 350 mg soluble/dispersible 30 mg, Diltiazem S, T Tablets 60 mg Glyceryl P,S,T Sublingual Tablets 0.5 mg Trinitrate Injection 5mg/ml Isosorbide 5 P,S,T Tablets 10 mg, Mononitrate/ 20 mg Dinitrate Tablets 25 mg, 50 mg Metoprolol P,S,T Injection 1mg/ml Added Medicines Clopidogrel T Tablets 75 mg 12.2: Antiarrhythmic medicines Route of Medicines Category Strengths Administration Adenosine S,T Injection 3 mg/ml 100 mg, Tablets Amiodarone S, T 200 mg 50 mg/ml (3 ml Injection ampoule) Diltiazem S, T Tablets 30 mg, Page 55 of 127 56.

60 mg T Injection 5 mg/ ml Esmolol T 10 mg / ml Injection Lignocaine S, T Injection 1%, 2%HydrochlorideProcainamide Tablets 250 mg THydrochloride Injection 100mg/ml Tablets 40 mg, 80 mg Verapamil S, T Injection 2.5mg/ml 12.3: Antihypertensive medicines Route of Medicines Category Strengths Administration 2.5 mg,Amlodipine P,S,T Tablets 5 mg Atenolol P,S,T Tablets 50 mg 2.5 mg, Enalapril P,S,T Tablets 5mg Maleate T Injection 1.25mg/ml Losartan S, T Tablets 25 mg, Potassium 50 mgMethyldopa P,S, T Tablets 250 mg Capsules 5 mg, 10mg Tablets Nifedipine S, T 10mg, 20mg Sustained release tablets or 10mg, 20mg capsules Sodium T Injection 50 mg/ 5 mlNitroprusside Page 56 of 127 57.Added MedicinesHydrochlorthiazi P,S,T Tablets 12.5, 25 mg de 12.4: Medicines used in heart failure Route of Medicines Category Strengths Administration Digoxin S, T Tablets 0.25 mg Injection 0.25 mg/ml Elixir 0.05 mg/ml Dobutamine S, T Injection 50 mg / ml Dopamine S,T Injection 40 mg / ml Hydrochloride 12.5: Antithrombotic medicines Route of Medicines Category Strengths Administration 75mg, Acetyl salicylic 100mg, P,S,T Tablets acid 350 mg soluble/dispersible S, T Injection Heparin 1000 IU /ml Sodium 5000 IU/ml 750,000 IU S, T Injection Streptokinase 15,00,000 IU Page 57 of 127 58.

T Injection 500,000 Urokinase IU/ml 10,00,000 IU/ml New Category - ADDED 12.6 Hypolipidemic MedicinesAtorvastatin P,S,T Tablets 5 mg, 10 mg Page 58 of 127 59.Section: 13 –Dermatological medicines (Topical) 13.1: Antifungal medicines Route of Medicines Category Strengths Administration Ointment or Miconazole P,S,T 2% Cream 13.2: Antiinfective medicines Route of Medicines Category Strengths Administration Acyclovir S, T Cream 5% Framycetin P,S,T Cream 0.5% SulphateMethylrosanilini um Chloride P,S,T Aqueous solution 0.5%(Gentian Violet) Neomycin + P,S,T Ointment 5 mg + 500 IU / g Bacitracin Povidone Solution or P,S,T 5% Iodine Ointment Silver P,S,T Cream 1% Sulphadiazine 13.3: Antiinflammatory and antipruritic medicines Route of Medicines Category Strengths Administration Betamethason Cream / P,S,T 0.05% e Dipropionate Ointment Calamine P,S,T Lotion 13.4: Astringent Medicines Route of Medicines Category Strengths Administration Page 59 of 127 60.Zinc Oxide P,S,T Dusting Powder 13.5: Medicines affecting skin differentiation and proliferation Route of Medicines Category Strengths Administration Coal Tar P,S,T Solution 5% Dithranol T Ointment 0.1-2% Glycerin P,S,T Solution Salicylic Acid P,S,T Solution 5% 13.6: Scabicides and Pediculicides Route of Medicines Category Strengths AdministrationBenzyl benzoate P,S,T Lotion 25 % Added Medicines Cream 5% Permethrin S,T Lotion 1%, 5% Page 60 of 127